- Analysis
- Barani Krishnan
- 32
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. The company’s lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary syndrome, and post COVID-19 conditions. It has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company is headquartered in Calgary, Canada.
Metrics to compare | RVX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRVXPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.9x | −2.8x | −0.6x | |
PEG Ratio | −0.06 | −0.08 | 0.00 | |
Price/Book | −0.1x | 1.9x | 2.6x | |
Price / LTM Sales | - | 3.7x | 3.1x | |
Upside (Analyst Target) | - | 244.7% | 47.1% | |
Fair Value Upside | Unlock | 11.4% | 8.1% | Unlock |